Director, Biostatistics, Late Clinical Stage Revolution Medicines, Inc.Director, Biostatistics, Late Clinical StageRedwood City, CA$211,000–$264,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Opportunity: Playing a critical role as a lead statistician for clinical program(s) and studies in clinical late-stage development and the subject matter expert (SME) in Biostatistics within Quantitative Sciences function, this position is to provide statistical leadership and support for clinical development strategy and clinical studies through product life cycle.
Associate Director, Clinical Data Management Summit Therapeutics plcAssociate Director, Clinical Data ManagementPalo Alto, CALeads, designs and/or oversees eCRF design, eCRF specifications, eCRF completion guidelines, annotated CRFs, User Acceptance Testing, query logic, edit checks, data query resolution, SAE reconciliation between clinical and pharmacovigilance databases, vendor data reconciliation & cleaning, data migration and database closeout for clinical trials. Additionally, the position will manage data management staff, Contract Research Organizations (CROs) and service providers' activities in overseeing the data management process life cycle in coordination with internal Biostatistics, Clinical, and Regulatory teams to ensure the accurate, efficient, and complete data collection for clinical trials.
Medical Director, Early-Stage Clinical Development Revolution Medicines, Inc.Medical Director, Early-Stage Clinical DevelopmentRedwood City, CA$295,000–$339,000 / yearHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Early Clinical Development Revolution Medicines, Inc.Executive Director, Early Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Revolution Medicines, Inc.Executive Director, GCP QA (Good Clinical Practice, Quality Assurance)Redwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Minimum of 15 years of experience in the pharmaceutical or biotechnology industry, including at least 10 years in GCP QA or clinical quality leadership roles, with demonstrated experience leading and hosting regulatory inspections (e.g., FDA BIMO, EMA, MHRA, PMDA).
Senior Medical Director, Early-Stage Clinical Development Revolution Medicines, Inc.Senior Medical Director, Early-Stage Clinical DevelopmentRedwood City, CA$346,000–$397,000 / yearHas demonstrated collaborative behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Executive Director, Clinical Supply Chain Revolution Medicines, Inc.Executive Director, Clinical Supply ChainRedwood City, CA$265,000–$331,000 / yearThe company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Executive Director, Clinical Development Revolution Medicines, Inc.Executive Director, Clinical DevelopmentRedwood City, CA$265,000–$331,000 / yearHas demonstrated collaborate behaviors on enterprise-level strategic initiatives with a variety of internal and external partners and stakeholders - including clinical investigators/clinicians, scientists and key opinion leaders (KOLs), as well as internal groups, including other groups in development, research, business development, commercial, legal, etc. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.
Associate Director, Clinical Operations Compliance & Training Revolution MedicinesAssociate Director, Clinical Operations Compliance & TrainingRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.
Associate Director, Clinical Quality Assurance Revolution MedicinesAssociate Director, Clinical Quality AssuranceRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Associate Director, Clinical Biomarker Development Revolution MedicinesAssociate Director, Clinical Biomarker DevelopmentRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Associate Director in Clinical Biomarker Development team, within Translational Medicine will play a key role in the design, execution, and interpretation of clinical biomarker strategies across Revolution Medicine’s oncology pipeline.
Associate Director, Biostatistics Clinical Late Stage Revolution MedicinesAssociate Director, Biostatistics Clinical Late StageRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Director, Clinical Data Management Revolution MedicinesDirector, Clinical Data ManagementRedwood City, CaliforniaThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Associate Director, Clinical Data Management Revolution MedicinesAssociate Director, Clinical Data ManagementRedwood City, California$186,000–$233,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Provides CDM oversight of outsourced and partner-resourced clinical trials including scoping trials, project management, relationship management, approval of deliverables, and coordination of internal reviewers.
Senior Director, Clinical Data Management Revolution MedicinesSenior Director, Clinical Data ManagementRedwood City, California$244,000–$305,000 / yearThe company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. The Senior Director of Clinical Data Management provides high-level leadership for data management functions within clinical research, focusing on strategic development, operational execution, and regulatory compliance to ensure data integrity for clinical trials.
Senior Director, Clinical Research-Medical Director (Oncology) Vir BiotechnologySenior Director, Clinical Research-Medical Director (Oncology)San Francisco, CA$235,500–$329,500 / yearThe role requires a physician leader with a strong track record of serving as a Medical Monitor and Clinical Research Physician, partnering closely with Clinical Operations, Clinical Scientists, Pharmacovigilance, Biometrics, and Regulatory teams to ensure safe, high-quality study execution. The Senior Director, Clinical Research (Oncology) will serve as a Medical Director/Medical Monitor within Oncology Clinical Development, providing medical leadership for ongoing clinical trials and ensuring the safety of patients enrolled across Vir Bio's oncology studies.
Associate Medical Director, Clinical Development - Job ID: 1912, 1913, 1914 Ascendis PharmaAssociate Medical Director, Clinical Development - Job ID: 1912, 1913, 1914Palo Alto, CA$255,000–$265,000 / yearGuided by our core values of Patients, Science, and Passion, we use our TransCon® drug development platform to fulfill our mission of developing new and potentially best-in-class therapies to address unmet medical needs. Presentation of candidates without written permission from the Ascendis Pharma Inc Human Resources team (specifically from: Talent Acquisition Partner or Human Resources Director) is not allowed.
Senior Director, Clinical Operations BigHat BiosciencesSenior Director, Clinical OperationsSan Mateo, CaliforniaClinical Document Generation: Manage the preparation and lifecycle of key clinical documents, including protocols, informed consent forms, investigator brochures, clinical study reports, and regulatory submissions, ensuring accuracy, timeliness, and compliance with applicable guidelines. Translational Biomarker Support: Partner closely with the Translational Biomarker team to ensure clinical operations infrastructure supports biomarker sample collection, handling, and logistics across all trial sites.
Senior Director, Clinical Research-Infectious Disease Vir Biotechnology, Inc.Senior Director, Clinical Research-Infectious DiseaseSan Francisco, CA$235,500–$329,500 / yearVir Biotechnology is looking for a Senior Director, Clinical Research-Infectious Disease to facilitate late‑stage clinical development for our hepatitis delta (HDV) portfolio, with a primary focus on activities supporting the Phase III clinical program and health authority submission activities. Reporting to the VP, Clinical Research, this senior leader will serve as the key clinical voice in shaping and executing the clinical development strategy You will concentrate on advancing our HDV assets through global Phase III,BLA‑enabling activities and support on relevant commercial activities.
Senior Director, Clinical Research-Oncology Vir Biotechnology, Inc.Senior Director, Clinical Research-OncologySan Francisco, CA$235,500–$329,500 / yearOversee clinical science deliverables for assigned studies, including protocols and amendments, informed consent forms (ICFs), case report form (CRF) design and data review strategies, and clinical study reports (CSRs) as well as the clinical sections of regulatory submissions. This role requires an experienced MD, PhD or PharmD with deep expertise in oncology drug development and a proven track record of leading clinical research teams through complex development programs, from first‑in‑human through registration.